In particular, pathological responses at surgery seem to work as a surrogate of survival. 1ġEuropean Institute of Oncology, IRCCS, Milan 2University of Turin, Turinīackground: Neo-adjuvant approaches in locally advanced melanoma have been shown to improve outcomes and facilitate translational research in order to identify biomarkers of response and resistance. NEOADJUVANT IPILIMUMAB/NIVOLUMAB FOLLOWED BY ADJUVANT NIVOLUMAB IN LOCALLY ADVANCED OR OLIGOMETASTATIC MELANOMAįerrucci P.F. Influenza vaccination should be recommended in ICI-treated cancer patients adjuvated vaccines may be preferred in this patient population. Adverse events (AEs) to flu vaccine were rare and mild (1.6%, grade 1-2).Ĭonclusions: The flu vaccine administration was not correlated with ILI incidence, but it significantly reduced ILI complications, with no ILI-related deaths in vaccinated patients. No difference has been found between trivalent and quadrivalent vaccines (p=0.09). Among vaccinated patients, those receiving adjuvated vaccines had lower incidence of ILI (4.8% vs 9.9%, p=0.046). Hospitalization was infrequent among vaccinated patients (only 3 of 10 patients requiring hospital admission due to ILI were vaccinated) and ILI lethality was 0%, whilst it was 4.5% in unvaccinated patients. Nevertheless, the vaccine administration was related to significantly lower rate of ILI complications: 12.8% vs 40.9%, p=0.002. The time-adjusted ILI incidence, in terms of influenza-free survival (IFS), was similar in vaccinated and unvaccinated patients (6-months IFS 91.4% vs 89.7% respectively, p=0.92). The ILI incidence was not different according to influenza vaccination: the incidence of ILI was 8.2% in vaccinated vs 7.3% in unvaccinated patients (p=0.57). Patients receiving the flu vaccine were significantly more frequently elderly (p<0.0001), former or active smokers (p<0.0001), affected by lung cancer (p=0.017) and by non-cancer comorbidities (p<0.0001) when compared to unvaccinated patients. The ILI incidence was 7.7% (91 patients). Of them, 48.8% (574) received flu vaccination. Results: The study enrolled 1279 patients 1177 patients were evaluable for the primary endpoint analysis. Secondary endpoints regarded ILI severity and lethality and flu vaccine safety. The primary endpoint was the incidence of influenza-like illness (ILI) until April 30, 2020. Methods: The prospective, multicenter, observational INVIDIa-2 study investigated the clinical efficacy of influenza vaccination in advanced cancer patients receiving ICI between October 2019 and January 2020. The retrospective INVIDIa study suggested that flu vaccine could be ineffective in these patients. Currently, there are no robust data supporting the efficacy, safety and recommendation for influenza vaccination in cancer patients receiving ICI. Pascale, Napoli 6Ospedale San Bortolo Azienda ULSS8 Berica - Distretto Est, Vicenza 7Azienda Sanitaria Universitaria Friuli Centrale, Udine 8IRCCS Istituto Tumori “Giovanni Paolo II”, Bari 9Azienda Ospedaliero Universitaria Careggi, Firenze 10Azienda Ospedaliera di Alessandria, Firenze 11Azienda Ospedaliero-Universitaria Sant’Andrea, Roma 12Istituto Oncologico Veneto IOV - IRCCS, Padova 13Policlinico Gemelli - Università La Sapienza, Roma 14Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano 15Ospedale Mauriziano - Università degli Studi di Torino, Torinoīackground: The susceptibility of advanced cancer patients treated with immune checkpoint inhibitors (ICI) for viral infections has not been investigated. 4ġAzienda Ospedaliero-Universitaria di Parma, Parma 2Istituto Nazionale Tumori Regina Elena, Roma 3IRCCS Istituto Nazionale Tumori di Milano, Milano 4Istituto Scientifico Romagnolo per lo Studio e la Cura de Tumori (IRST) IRCCS, Meldola 5IRCCS Istituto Nazionale Tumori G. THE MULTICENTER, PROSPECTIVE, OBSERVATIONAL INVIDIA-2 STUDY (A FICOG STUDY)īersanelli M. INFLUENZA VACCINE INDICATION DURING THERAPY WITH IMMUNE CHECKPOINT INHIBITORS: A TRANSVERSAL CHALLENGE. G - Neuroendocrine Tumours and Sarcomas.
E27 – The Abstract has been Withdrawn at the Request of the Authors.C - Gastrointestinal (Non-Colorectal) Cancers.B - Gastrointestinal (Colorectal) Cancers.
0 kommentar(er)
